Document Detail


Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease.
MedLine Citation:
PMID:  2787683     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plasma or serum extrinsic pathway inhibitor (EPI) activity was measured in 24 patients with disseminated intravascular coagulation (DIC) and in 23 patients with severe hepatocellular disease. EPI was measured as activity in a test sample that inhibited factor VIIa/tissue factor (TF)-catalyzed activation of 3H-factor IX (activation peptide release) in the presence of factor X. Of the 24 patients with DIC, 13 had sepsis and five had metastatic carcinoma, disorders in which tissue factor is believed to initiate DIC. EPI activity ranged from 68% to 300% (mean 134% +/- 50%). Serial measurements in nine patients failed to show depletion of EPI activity coincident with worsening DIC. DIC induced by tissue factor or other activating materials may progress despite normal EPI levels. In the patients with liver disease, of whom 15 had decompensated chronic hepatocellular disease (two fatal cases) and eight had acute fulminant liver failure (seven fatal cases), plasma or serum EPI activity varied from less than 20% to 194%. Values were distributed in a bimodal fashion. EPI activity could not be correlated with either the etiology of the liver disease or the degree of prolongation of the prothrombin time. Patients with chronic hepatocellular disease who survived had normal or elevated EPI activity. Patients with fatal hepatic dysfunction had low, normal, or high values for EPI activity. This must mean that secretion of EPI from cells other than hepatocytes can maintain normal plasma EPI levels.
Authors:
T A Warr; L V Rao; S I Rapaport
Related Documents :
2514783 - Cutaneous fibrinolytic potential, tpa dependent, is reduced in behçet's disease.
9763553 - Treatment of acquired von willebrand syndrome in patients with monoclonal gammopathy of...
14990843 - Us-guided percutaneous cholecystostomy: features predicting culture-positive bile and c...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Blood     Volume:  74     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1989-09-07     Completed Date:  1989-09-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  994-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, University of California, San Diego 92103.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acinetobacter Infections / blood,  complications
Adult
Chronic Disease / blood
Disseminated Intravascular Coagulation / blood*,  etiology
Factor VII / antagonists & inhibitors*
Factor VIIa
Female
Humans
Liver Diseases / blood*,  complications
Male
Mediastinitis / blood,  complications
Middle Aged
Stomach Neoplasms / blood,  secondary
Thromboplastin / antagonists & inhibitors*
Grant Support
ID/Acronym/Agency:
HL07107/HL/NHLBI NIH HHS; HL27234/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
9001-25-6/Factor VII; 9035-58-9/Thromboplastin; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant ...
Next Document:  Alcoholic and non-alcoholic liver disease in relation to alcohol consumption in Scotland, 1978-84. P...